Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma - 10/10/23
Doi : 10.1016/j.hoc.2023.05.007
Mark P. Hamilton, MD, PhD a, b, c, ⁎ 
, David B. Miklos, MD, PhD a, b
, David B. Miklos, MD, PhD a, b a Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
b Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
c Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
∗Corresponding author.
Résumé |
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary therapy increasingly used in the treatment of non-Hodgkin B-cell lymphoma. This review focuses on the use of CAR T-cell therapy in aggressive B-cell lymphoma including clinical indications, known short- and long-term toxicity, mechanisms of CAR T-cell efficacy and tumor resistance, and future directions in the treatment of aggressive lymphoma with CAR T-cell therapy.
Le texte complet de cet article est disponible en PDF.Keywords : CAR T-cell, Large B-cell lymphoma, Aggressive lymphoma, CAR T-cell toxicity, CAR T-cell resistance, Review, CD19
Plan
© 2023
Elsevier Inc. Tous droits réservés.
Vol 37 - N° 6
P. 1053-1075 - décembre 2023 Retour au numéro
Article précédent
- The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia
- Susan E. McClory, Shannon L. Maude
- Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
- Parth S. Shah, Caron A. Jacobson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?